Vascular endothelial growth factor-2 gene therapy - Corautus Genetics
Alternative Names: VEGF-2 gene therapy - Corautus GeneticsLatest Information Update: 11 Jun 2007
Price :
$50 *
At a glance
- Originator Human Genome Sciences
- Developer Boston Scientific Corporation
- Class Cytokine genes; Gene therapies; Growth factors
- Mechanism of Action Angiogenesis inducing agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Angina pectoris; Coronary artery restenosis; Diabetic neuropathies; Ischaemic heart disorders; Vascular disorders
Most Recent Events
- 06 Jun 2007 Corautus Genetics has been acquired and merged into VIA Pharmaceuticals
- 03 Nov 2006 Suspended - Phase-I for Diabetic neuropathies in USA (Parenteral)
- 03 Nov 2006 Suspended - Phase-II for Angina pectoris in USA (Intracoronary)